Literature DB >> 10749119

EWS-FLI1, EWS-ERG, and EWS-ETV1 oncoproteins of Ewing tumor family all suppress transcription of transforming growth factor beta type II receptor gene.

Y H Im1, H T Kim, C Lee, D Poulin, S Welford, P H Sorensen, C T Denny, S J Kim.   

Abstract

Ewing sarcoma-specific chromosomal translocations fuse the EWS gene to a subset of ets transcription factor family members, most commonly the FLI1 gene and less frequently ERG, ETV1, E1A-F, or FEV. These fusion proteins are thought to act as aberrant transcription factors that bind DNA through their ets DNA binding domain. Recently, we have shown (K-B. Hahm et al., Nat. Genet., 23: 222-227, 1999) that the transforming growth factor beta (TGF-beta) type II receptor (TGF-beta RII), a putative tumor suppressor gene, is a target of the EWS-FLI1 fusion protein. Here, we also examined effects of EWS-ETV1 and EWS-ERG on expression of the TGF-beta RII gene. We show that relative to the control, NIH-3T3 cell lines stably transfected with the EWS-FLI1, EWS-ERG, or EWS-ETV1 gene fusion express reduced levels of TGF-beta RII mRNA and protein, and that these cell lines have reduced TGF-beta sensitivity. Cotransfection of these fusion genes and the TGF-beta RII promoter suppresses TGF-beta RII promoter activity and also FLI1-, ERG-, or ETV1-induced promoter activity. These results indicate that transcriptional repression of TGF-beta RII is an important target of the EWS-FLI1, EWS-ERG, or EWS-ETV1 oncogene, and that EWS-ets fusion proteins may function as dominant negative forms of ets transcription factors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10749119

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

Review 1.  Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets.

Authors:  Stephen L Lessnick; Marc Ladanyi
Journal:  Annu Rev Pathol       Date:  2011-09-19       Impact factor: 23.472

2.  Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement.

Authors:  Maisa Yoshimoto; Anthony M Joshua; Susan Chilton-Macneill; Jane Bayani; Shamini Selvarajah; Andrew J Evans; Maria Zielenska; Jeremy A Squire
Journal:  Neoplasia       Date:  2006-06       Impact factor: 5.715

Review 3.  Advances in sarcoma genomics and new therapeutic targets.

Authors:  Barry S Taylor; Jordi Barretina; Robert G Maki; Cristina R Antonescu; Samuel Singer; Marc Ladanyi
Journal:  Nat Rev Cancer       Date:  2011-07-14       Impact factor: 60.716

4.  Inducible expression of chimeric EWS/ETS proteins confers Ewing's family tumor-like phenotypes to human mesenchymal progenitor cells.

Authors:  Yoshitaka Miyagawa; Hajime Okita; Hideki Nakaijima; Yasuomi Horiuchi; Ban Sato; Tomoko Taguchi; Masashi Toyoda; Yohko U Katagiri; Junichiro Fujimoto; Jun-Ichi Hata; Akihiro Umezawa; Nobutaka Kiyokawa
Journal:  Mol Cell Biol       Date:  2008-01-22       Impact factor: 4.272

5.  PDGF-C is an EWS/FLI induced transforming growth factor in Ewing family tumors.

Authors:  J P Zwerner; W A May
Journal:  Oncogene       Date:  2001-02-01       Impact factor: 9.867

6.  A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs.

Authors:  E L McKinsey; J K Parrish; A E Irwin; B F Niemeyer; H B Kern; D K Birks; P Jedlicka
Journal:  Oncogene       Date:  2011-06-06       Impact factor: 9.867

7.  Molecular Mechanism of β-Catenin Signaling Pathway Inactivation in ETV1-Positive Prostate Cancers.

Authors:  Sharif Morsalin; Chunshu Yang; Jinbo Fang; Sampreet Reddy; Shubhalaxmi Kayarthodi; Ed Childs; Roland Matthews; Veena N Rao; E Shyam P Reddy
Journal:  J Pharm Sci Pharmacol       Date:  2015-09

8.  Erg cooperates with TGF-β to control mesenchymal differentiation.

Authors:  Megan K Cox; Brittany L Appelboom; Ga I Ban; Rosa Serra
Journal:  Exp Cell Res       Date:  2014-08-17       Impact factor: 3.905

9.  Oncogenic fusion protein EWS/FLI1 down-regulates gene expression by both transcriptional and posttranscriptional mechanisms.

Authors:  Kelly A France; Jennifer L Anderson; Ann Park; Christopher T Denny
Journal:  J Biol Chem       Date:  2011-04-28       Impact factor: 5.157

Review 10.  Diagnostic and prognostic sarcoma signatures.

Authors:  Elai Davicioni; Daniel H Wai; Michael J Anderson
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.